rs104894135 — CYP17A1 Ser106Pro

Pathogenic missense variant in CYP17A1 causing complete loss of 17α-hydroxylase/17,20-lyase activity; homozygotes develop 17α-hydroxylase deficiency (hypertension, hypokalemia, and sexual infantilism), while heterozygous carriers show subclinical enzyme reduction detectable by ACTH stimulation testing.

See your personal result for CYP17A1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CYP17A1 Ser106Pro — The Steroidogenesis Switch That Fails

At the crossroads of cortisol synthesis and sex steroid production sits a single enzyme, CYP17A1 — cytochrome P450 17α-hydroxylase/17,20-lyase11 cytochrome P450 17α-hydroxylase/17,20-lyase
A bifunctional enzyme that performs two consecutive reactions in the steroid hormone biosynthesis pathway. Without it, the adrenal gland cannot make cortisol or sex steroid precursors. The rs104894135 variant (c.316T>C, p.Ser106Pro) is a rare but well-documented pathogenic missense change that abolishes CYP17A1 function. When two copies are inherited, the result is a distinctive syndrome: high blood pressure, low potassium, and absent pubertal development — the classic triad of 17α-hydroxylase deficiency (17OHD).

The Mechanism

CYP17A1 catalyzes two sequential reactions in the adrenal cortex and gonads. First, 17α-hydroxylation22 17α-hydroxylation
Adds a hydroxyl group to the 17-position of pregnenolone or progesterone, producing 17α-hydroxypregnenolone or 17α-hydroxyprogesterone — precursors required for cortisol synthesis. Second, 17,20-lyase activity33 17,20-lyase activity
Cleaves the C17–C20 bond, converting 17α-hydroxypregnenolone to DHEA and 17α-hydroxyprogesterone to androstenedione — the essential step that enters the sex steroid biosynthesis pathway.

The Ser106Pro substitution replaces a small, flexible serine at position 106 with proline, an amino acid that introduces a rigid kink into protein secondary structure. Multiple ClinVar submitters, including GeneDx and Labcorp/Invitae, have confirmed through functional assays that this substitution causes a complete loss of catalytic activity. Without CYP17A1 function, the adrenal gland cannot produce cortisol or sex steroid precursors. Instead, steroidogenesis is shunted into the mineralocorticoid pathway: 11-deoxycorticosterone (DOC) accumulates, driving sodium retention, hypertension, and hypokalemia. The pituitary responds to absent cortisol with chronically elevated ACTH, which drives adrenal hyperplasia — sometimes visible on CT imaging as bilateral adrenal enlargement.

The Evidence

The largest summary of 17OHD comes from a meta-analysis of 465 patients across 178 published studies44 meta-analysis of 465 patients across 178 published studies
Willemsen et al. 2025, J Clin Endocrinol Metab. Hypertension was present in 57% of patients, hypokalemia in 45%, and primary amenorrhea in 38% of females. The meta-analysis confirmed that more severe mutations — including complete loss-of-function variants like p.Ser106Pro — are associated with hypocortisolism and complete absence of secondary sexual development, while partial-function mutations produce milder phenotypes.

The Ser106Pro homozygous phenotype is directly documented in a 2025 case series of two 46,XX girls55 2025 case series of two 46,XX girls
Li et al. 2025, J Clin Res Pediatr Endocrinol. Case 1 — homozygous for p.S106P — presented with primary amenorrhea, infantile genitalia, absent axillary and pubic hair, hypertension, and hypokalemia. Low cortisol and reduced 17α-hydroxyprogesterone confirmed complete enzyme loss. Both patients in the series responded well to hormone replacement therapy.

In heterozygous carriers, Qiao et al. 201066 Qiao et al. 2010
Clinical Endocrinology demonstrated that while carriers are clinically asymptomatic, ACTH stimulation testing reveals measurable enzyme insufficiency: lower basal and stimulated cortisol, higher corticosterone-to-cortisol ratios, and elevated progesterone relative to 17α-hydroxyprogesterone. These subclinical findings in carriers support biochemical screening when this variant is identified in a family.

The condition is frequently misdiagnosed77 misdiagnosed
A 2025 case report documented three incorrect diagnoses over years before genetic testing confirmed the CYP17A1 compound heterozygous mutation, underscoring the importance of genetic confirmation when the clinical triad is present.

Practical Actions

Treatment for homozygous individuals is straightforward once diagnosed: glucocorticoid replacement (typically hydrocortisone) suppresses ACTH, halts DOC excess, and normalizes blood pressure and potassium. Sex hormone replacement is added to induce and maintain pubertal development. The blood pressure in 17OHD is mineralocorticoid-mediated and responds to glucocorticoid suppression of ACTH88 mineralocorticoid-mediated and responds to glucocorticoid suppression of ACTH
Unlike essential hypertension, the hypertension of 17OHD resolves with adequate glucocorticoid replacement — making accurate diagnosis essential before antihypertensive treatment is started, not conventional antihypertensive drugs.

For heterozygous carriers, the primary action is genetic counseling and family planning awareness: carrier couples face a 25% chance of an affected child with each pregnancy. Biochemical carrier confirmation via ACTH stimulation testing may be warranted in the clinical context.

Interactions

CYP17A1 loss-of-function creates a cascade through the entire steroidogenesis network. The upstream substrate pregnenolone accumulates and is redirected toward the mineralocorticoid (DOC, corticosterone) branch. The downstream deficit — complete absence of DHEA and androstenedione — means no sex steroids from the adrenal gland whatsoever; the gonads are also affected because the same enzyme operates in testicular and ovarian tissue.

Compound heterozygosity with other CYP17A1 loss-of-function mutations (such as the Asian founder variants p.H373L, p.W406R, or p.Y329Kfs) is well-documented and produces the same complete-deficiency phenotype. Related pathogenic variants in the same gene that are also tracked in published case series include the frameshift deletion p.D487_F489del and the missense p.W406R, which are the second and third most common CYP17A1 mutations globally.

Genotype Interpretations

What each possible genotype means for this variant.

AA Non-Carrier Normal

Common genotype — no CYP17A1 Ser106Pro variant detected

You have two copies of the common reference allele at rs104894135. This is the genotype present in the vast majority of people — the G alternate allele causing Ser106Pro occurs at a frequency of roughly 1–2 per 100,000 chromosomes globally. Your CYP17A1 steroidogenesis enzyme is not affected by this variant.

AG Heterozygous Carrier Carrier

One copy of the Ser106Pro variant — carrier of a CYP17A1 pathogenic mutation

Qiao et al. 2010 (PMID 19508587) examined genotype-proven heterozygous CYP17A1 carriers and found that, compared to normal controls, carriers showed: - Lower basal and ACTH-stimulated cortisol concentrations - Higher corticosterone-to-cortisol ratios at baseline and after stimulation - Elevated progesterone relative to 17α-hydroxyprogesterone in male carriers

These differences are biochemically detectable but do not cause symptoms in isolation. The subclinical reduction in 17α-hydroxylase reserve may theoretically affect the stress cortisol response under high physiological demand, though this has not been formally studied for this specific variant.

This variant is extremely rare — fewer than 2 in 100,000 chromosomes globally in large population databases. Carriers of this variant found through clinical genetic testing (e.g., following the diagnosis of an affected family member) should receive formal genetic counseling.

GG Homozygous — 17α-Hydroxylase Deficiency Homozygous

Two copies of Ser106Pro — complete 17α-hydroxylase/17,20-lyase deficiency

The clinical triad of 17OHD — hypertension, hypokalemia, and absent secondary sexual development — emerges because CYP17A1 sits at the branch point between mineralocorticoid and sex steroid synthesis. In the absence of this enzyme:

  1. Cortisol deficit: ACTH rises continuously (losing negative feedback), driving bilateral adrenal hyperplasia. Cortisol is absent, creating risk for adrenal crisis during physiological stress (illness, surgery, injury).

  2. Mineralocorticoid excess: The cortisol precursor pool is instead shunted to corticosterone and 11-deoxycorticosterone (DOC), potent mineralocorticoids that cause hypertension and hypokalemia. This hypertension is not essential hypertension — it is ACTH-driven and resolves with glucocorticoid replacement.

  3. Sex steroid deficiency: Neither the adrenal gland nor the gonads can produce DHEA or androstenedione. In 46,XX individuals: primary amenorrhea and sexual infantilism. In 46,XY individuals: external female phenotype, cryptorchidism, and primary amenorrhea.

Li et al. 2025 (PMID 36800681) documented the specific phenotype of a girl homozygous for p.S106P: primary amenorrhea, infantile genitalia, absent pubic and axillary hair, hypertension, and hypokalemia. Both patients in that series responded well to glucocorticoid and sex hormone replacement.

Willemsen et al. 2025 (PMID 39500362) confirmed across 465 cases that complete loss-of- function variants produce the most severe phenotype, with hypocortisolism and complete sexual infantilism, in contrast to partial-function mutations which allow partial pubertal development.

Misdiagnosis is common — hypertension in a young person without other risk factors, combined with primary amenorrhea, is the diagnostic key. A 2025 case report (PMID 40725971) described three successive misdiagnoses before CYP17A1 compound heterozygous mutations were found.